Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Neurochirurgie ; 69(2): 101417, 2023 Mar.
Article in English | MEDLINE | ID: mdl-36827763

ABSTRACT

PURPOSE: We assessed the impact of frailty on surgical outcomes, survival, and functional dependency in elderly patients harboring a glioblastoma, isocitrate dehydrogenase (IDH)-wildtype. METHODS: We retrospectively reviewed records of old and frail patients surgical treated at a single neurosurgical institution between January 2018 to May 2021. Inclusion criteria were: (1) neuropathological diagnosis of glioblastoma, IDH-wildtype; (2) patient≥65years at the time of surgery; (3) available data to assess the frailty index according to the 5-modified Frailty Index (5-mFI). RESULTS: A total of 47 patients were included. The 5-mFI was at 0 in 11 cases (23.4%), at 1 in 30 cases (63.8%), at 2 in two cases (4.2%), at 3 in two cases (4.2%), and at 4 in two cases (4.2%). A gross total resection was performed in 26 patients (55.3%), a subtotal resection was performed in 13 patients (27.6%), and a biopsy was performed in 8 patients (17.1%). The rate of 30-day postoperative complications was higher in the biopsy subgroup and in the 5-mFI=4 subgroup. Gross total resection and age≤70years were independent predictors of a longer overall survival. Sex, 5-mFI, postoperative complications, and preoperative Karnofsky Performance Status score did not influence overall survival and functional dependency. CONCLUSION: In patients≥65years harboring a glioblastoma, IDH-wildtype, gross total resection remains an independent predictor of longer survival and good postoperative functional recovery. The frailty, assessed by the 5-mFI score, does not influence surgery and outcomes in this dataset. Further confirmatory analyses are required.


Subject(s)
Frailty , Glioblastoma , Humans , Aged , Glioblastoma/genetics , Glioblastoma/surgery , Frailty/diagnosis , Frailty/complications , Isocitrate Dehydrogenase/genetics , Frail Elderly , Retrospective Studies , Postoperative Complications/etiology
2.
Vet Comp Oncol ; 16(3): 399-408, 2018 Sep.
Article in English | MEDLINE | ID: mdl-29508493

ABSTRACT

Unresectable or metastatic (advanced) primary pulmonary carcinoma (PPC) represents a therapeutic challenge where surgery may be contraindicated and the therapeutic role of maximum-tolerated dose (MTD) chemotherapy remains uncertain. This study was undertaken to explore the impact of metronomic chemotherapy (MC) in dogs with advanced PPC. Previously untreated dogs with advanced (T3 or N1 or M1) PPC, with complete staging work-up and follow-up data, receiving MC (comprising low-dose cyclophosphamide, piroxicam and thalidomide), surgery, MTD chemotherapy or no oncologic treatment were eligible for inclusion. For all patients, time to progression (TTP) and survival time (ST) were evaluated. Quality-of-life (QoL) was only evaluated in patients receiving MC. To assess QoL, owners of dogs receiving MC were asked to complete a questionnaire before and during treatment. Ninety-one dogs were included: 25 received MC, 36 were treated with surgery, 11 with MTD chemotherapy and 19 received no treatment. QoL was improved in dogs receiving MC. Median TTP was significantly longer in patients receiving MC (172 days) than patients undergoing surgery (87 days), receiving MTD chemotherapy (22 days), or no oncologic treatment (20 days). Median ST was similarly longer in patients receiving MC (139 days) than those undergoing surgery (92 days), MTD chemotherapy (61 days) and no oncologic treatment (60 days). In dogs with advanced PPC, MC achieved a measurable clinical benefit without significant risk or toxicity. This makes MC a potential alternative to other recognized management approaches.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Carcinoma/veterinary , Cyclophosphamide/administration & dosage , Dog Diseases/drug therapy , Lung Neoplasms/veterinary , Piroxicam/administration & dosage , Thalidomide/administration & dosage , Administration, Metronomic/veterinary , Animals , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma/drug therapy , Carcinoma/mortality , Carcinoma/therapy , Combined Modality Therapy/veterinary , Cyclophosphamide/therapeutic use , Dog Diseases/mortality , Dog Diseases/therapy , Dogs , Female , Lung Neoplasms/drug therapy , Lung Neoplasms/mortality , Lung Neoplasms/therapy , Male , Piroxicam/therapeutic use , Survival Analysis , Thalidomide/therapeutic use
3.
J Neurosurg Sci ; 53(1): 19-25; discussion 25-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19322132

ABSTRACT

AIM: Giant herniated thoracic disc (HTD) is a rare disease that, unlike other thoracic disc herniations of different size, need a different surgical management. The copresence of ''giant'' volume and calcification of the herniated disc heavily affects the surgical difficulty and is not elsewhere described. METHODS: Seven cases of surgically treated giant calcified HTDs were considered in this study. Five of them were females and two males, age range 18-63 years. Before and after surgery, all patients underwent computed tomography myelography, magnetic resonance imaging or both pre-and postoperatively. Functional outcomes were assessed using the Asia grading system preoperatively, immediately after surgery, and at long-term follow-up examination. The mean overall follow-up period was 36 months. All patients presented with various grades of myelopathy: according to the Asia impairment scale, two were grade B, four were grade C and one were grade D. Six patients underwent an anterior approach, i.e. thoracotomy, and one patients underwent a posterolateral approach, i.e. peduncolocostotrasversectomy. RESULTS: Based on an analysis of the long-term follow-up data, the Asia grade improved in five patients (71.4%), stabilized (no grade change) in one (14.3%), and worsened in one (14.3%). CONCLUSIONS: Giant calcified HTDs are particularly challenging surgical lesions and their volume and consistency are additional elements of difficulty. This article presents authors' personal experience on a small but extraordinary series of giant and calcified thoracic herniated discs and the problems encountered in the management of this peculiar pathology since an accurate surgical planning leads to better clinical results.


Subject(s)
Calcinosis , Intervertebral Disc Displacement/surgery , Thoracic Vertebrae/surgery , Adolescent , Adult , Female , Follow-Up Studies , Humans , Intervertebral Disc Displacement/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Myelography , Severity of Illness Index , Thoracic Vertebrae/pathology , Thoracotomy , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
4.
Acta Neurochir (Wien) ; 149(1): 83-6; discussion 86, 2007 Jan.
Article in English | MEDLINE | ID: mdl-17171297

ABSTRACT

The authors analysed the case of a 53-years-old woman who presented with an C5-D1 intra-extradural mass. Following subtotal removal, the tumour was histologically classified as meningothelial meningioma and no radiotherapy was recommended. The neuroradiological workup demonstrated that the lesion was stable one year after the operation but, a few months later a tumour recurrence with huge bone destruction was detected. The tumour was totally resected and a circumferential stabilization was performed. Histology remained unchanged but radiotherapy was now recommended. One year after a new recurrence was detected and the patient died. The authors discuss the extremely malignant behaviour of a tumour classified as benign.


Subject(s)
Meningeal Neoplasms/pathology , Meningioma/pathology , Neoplasm Recurrence, Local/pathology , Cervical Vertebrae , Fatal Outcome , Female , Humans , Meningeal Neoplasms/surgery , Meningioma/surgery , Middle Aged , Neoplasm Invasiveness , Neoplasm Recurrence, Local/surgery , Thoracic Vertebrae
5.
Minerva Gastroenterol Dietol ; 49(2): 135-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-16481979

ABSTRACT

AIM: Psychological and/or psychiatric disorders (PSY) and functional gastrointestinal disorders (FGID) are often linked. Pelvic floor dyssynergia (PFD) is one of the most frequent FGID, but few studies have investigated its possible relationship with PSY. The aim of the present study was to evaluate whether an increased prevalence of PSY, and of what types, exist in patients affected with PFD. METHODS: Thirty-four female patients PFD and 34 age- and gender-matched control subjects were evaluated. The prevalence rates of axis I psychiatric disorders (DSM IV) and of pathological temperaments (Schneider-Akiskal criteria) were determined. RESULTS: PSY were detected in 29 patients (85.3%) and in 11 controls (32.3%), (p=0.000). A family load was present in 7 patients (20.6%) and in 2 controls (5.9%), (NS). Sixteen patients (47.0%) and no control subjects were diagnosed as having axis I psychiatric disorders (p=0.000); anxiety disorders were the most frequently represented condition. A pathological temperament was found in 28 patients (82.3%) (primarily the phobic-anxious temperament) and in 11 control subjects (32.3%),(p=0.000). CONCLUSIONS: This study shows that there is a higher prevalence of PSY in PFD patients than in controls in particular, anxiety disorders and the phobic-anxious temperament. We would recommend that a psychiatric evaluation be carried out in patients with PFD, especially before starting rehabilitation therapy for obstructed defecation, as the presence of psychiatric disorders could alter the course and decrease the efficacy of such a rehabilitation program.

SELECTION OF CITATIONS
SEARCH DETAIL
...